MedTrace Logo

Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia

NCT05832125 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-04-27

No results posted yet for this study

Summary

In order to improve the outcome of relapsed and/or refractory T-cell precursor acute lymphoblastic leukemia (T-ALL) patients, and to facilitate the use of oncogenetic targeted therapies in these patients, we set up an observational cohort, collecting clinical and biological information's from patients with T-ALL in relapse or refractory, as well as the use or not of a targeted therapy. The analysis of the cohort will allow us to evaluate the impact of this therapeutic strategies on the patients' fate, and to facilitate access to innovation and personalized medicine for these patients.

Conditions

  • Relapsed/Refractory Acute Lymphoblastic Leukemia
  • T-cell Acute Lymphoblastic Leukemia

Sponsors & Collaborators

  • Versailles Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05832125 on ClinicalTrials.gov